[
  {
    "id": 1,
    "question": "属于负向急性时相反应蛋白的是",
    "options": ["A.铜蓝蛋白", "B.结合珠蛋白", "C.白蛋白", "D.C反应蛋白", "E.a抗胰蛋白酶"],
    "answer": "C"
  },
  {
    "id": 2,
    "question": "适合于蛋白质浓度较低的尿液和脑脊液中总蛋白测定的方法是",
    "options": ["A.凯氏定氮法", "B.双缩脲法", "C.酚试剂法", "D.直接紫外吸收法", "E.染料结合法"],
    "answer": "E"
  },
  {
    "id": 3,
    "question": "关于血清前白蛋白的叙述，错误的是",
    "options": ["A.前白蛋白即甲状腺素转运蛋白", "B.前白蛋白属于正向急性时相反应蛋白", "C.血清中前白蛋白下降是肝功能不全的灵敏指标", "D.血清中低水平的前白蛋白可指示蛋白质营养不良", "E.临床测定前白蛋白一般使用免疫比浊法"],
    "answer": "B"
  },
  {
    "id": 4,
    "question": "关于血清铜蓝蛋白的叙述，错误的是",
    "options": ["A.每分子血清铜蓝蛋白含6~8个铜原子，呈现蓝色", "B.血清铜蓝蛋白具有铁氧化酶的活性", "C.血清铜蓝蛋白可作为Wilson病的辅助诊断指标", "D.遗传性铜蓝蛋白缺乏症患者的大多数组织并没有铁的沉积", "E.血清铜蓝蛋白具有抑制膜脂质氧化的作用"],
    "answer": "D"
  },
  {
    "id": 5,
    "question": "可导致血清结合珠蛋白含量增高的疾病是",
    "options": ["A.肾病综合征", "B.溶血性贫血", "C.疟疾", "D.肝硬化", "E.急性病毒性肝炎"],
    "answer": "A"
  },
  {
    "id": 6,
    "question": "关于同型胱氨酸尿症是由于机体先天酶缺乏导致的叙述,正确的是",
    "options": ["A.苯丙氨酸羟化酶", "B.尿黑酸氧化酶", "C.延胡索酸乙酰乙酸酶", "D.脯氨酸氧化酶", "E.胱硫醚合成酶"],
    "answer": "E"
  },
  {
    "id": 7,
    "question": "关于血清蛋白质检测的临床意义的叙述,正确的是",
    "options": ["A.α₂巨球蛋白是血清中主要的蛋白酶抑制物,占血清中抑制蛋白酶活力的90%左右", "B.尿液β₂微球蛋白排泄量增加可反映肾小管功能损害", "C.具有家族史且45岁前发病的慢性阻塞性肺气肿患者,推荐检测α₁酸性糖蛋白", "D.α₁抗胰蛋白酶是反映溃疡性结肠炎活动性的指标", "E.转铁蛋白对急性溶血性疾病有一定的鉴别诊断价值"],
    "answer": "B"
  },
  {
    "id": 8,
    "question": "关于血清转铁蛋白的叙述，错误的是",
    "options": ["A.血清转铁蛋白浓度受到食物铁供应的影响", "B.血清转铁蛋白常用于贫血的鉴别诊断", "C.血清转铁蛋白是负向急性时相反应蛋白", "D.缺铁性贫血时,血清转铁蛋白水平下降,经铁剂有效治疗后恢复到正常水平", "E.铁负荷过量时,如血色病,血清转铁蛋白水平正常"],
    "answer": "D"
  },
  {
    "id": 9,
    "question": "关于α₁抗胰蛋白酶的叙述，错误的是",
    "options": ["A.血清中α₁抗胰蛋白酶含量虽然比α₂巨球蛋白多,但其仅占血清中抑制蛋白酶活力的10%左右", "B.具有正常功能的α₁抗胰蛋白酶的基因型为PiMM", "C.大约10% PiZZ型婴儿有持续性的阻塞性黄疸", "D.大约2% PiZZ型婴儿在幼年时会进展为肝功能衰竭", "E.大约90% PiZZ型个体在20~40岁时发生肺气肿"],
    "answer": "A"
  },
  {
    "id": 10,
    "question": "关于导致尿黑酸尿症的先天缺乏酶的叙述，正确的是",
    "options": ["A.酪氨酸酶", "B.酪氨酸转氨酶", "C.酪氨酸羟化酶", "D.尿黑酸氧化酶", "E.苯丙氨酸羟化酶"],
    "answer": "D"
  },
  {
    "id": 11,
    "question": "关于高尿酸血症的叙述，错误的是",
    "options": ["A.遗传性嘌呤代谢异常", "B.脂质代谢异常", "C.钙、磷代谢异常", "D.尿酸排泄障碍", "E.骨髓增生性疾病"],
    "answer": "C"
  },
  {
    "id": 12,
    "question": "关于痛风的临床特征的叙述，错误的是",
    "options": ["A.特征性急性关节炎", "B.痛风石形成", "C.尿酸性尿路结石", "D.慢性间质性肾炎", "E.游走性关节炎"],
    "answer": "E"
  },
  {
    "id": 13,
    "question": "关于C反应蛋白的叙述，错误的是",
    "options": ["A.C反应蛋白是第一个被认识的急性时相反应蛋白", "B.临床可用于评估炎症性疾病的活动度", "C.临床可用于新生儿败血症和脑膜炎的监测", "D.临床不可用于肾移植后排斥反应的监测", "E.超敏C反应蛋白可作为心血管疾病的独立危险因子"],
    "answer": "D"
  },
  {
    "id": 14,
    "question": "测定血清白蛋白时临床常规使用的方法是",
    "options": ["A.溴甲酚绿法", "B.凯氏定氮法", "C.双缩脲法", "D.酚试剂法", "E.免疫比浊法"],
    "answer": "A"
  },
  {
    "id": 15,
    "question": "导致血清中白蛋白含量增高的是",
    "options": ["A.肝硬化", "B.严重失水", "C.肾病综合征", "D.烧伤", "E.门静脉高压"],
    "answer": "B"
  },
  {
    "id": 16,
    "question": "血清蛋白质电泳分离时,泳动最慢的是",
    "options": ["A.白蛋白", "B.α₁球蛋白", "C.α₂球蛋白", "D.β球蛋白", "E.γ球蛋白"],
    "answer": "E"
  },
  {
    "id": 17,
    "question": "引起胰岛β细胞分泌释放胰岛素最重要的因素是",
    "options": ["A.血脂水平增加", "B.肠道蠕动增强", "C.血糖水平增加", "D.下丘脑受刺激", "E.肾上腺素的释放"],
    "answer": "C"
  },
  {
    "id": 18,
    "question": "关于胰岛素在生理浓度下的作用叙述，错误的是",
    "options": ["A.糖异生", "B.脂肪合成", "C.葡萄糖氧化", "D.葡萄糖透过细胞膜", "E.ATP、DNA及RNA合成"],
    "answer": "A"
  },
  {
    "id": 19,
    "question": "胰岛素对血糖的调节作用是",
    "options": ["A.抑制糖异生,促进糖原分解", "B.促进糖异生,促进糖原分解", "C.促进糖异生,抑制糖原分解", "D.抑制糖异生,抑制糖原分解", "E.促进糖原分解,促进糖有氧氧化"],
    "answer": "D"
  },
  {
    "id": 20,
    "question": "短期饥饿后体内分泌增加的激素主要是",
    "options": ["A.胰岛素", "B.肾上腺素", "C.甲状腺素", "D.胰高血糖素", "E.肾上腺皮质激素"],
    "answer": "D"
  },
  {
    "id": 21,
    "question": "关于胰岛素作用的叙述，正确的是",
    "options": ["A.胰岛素原生物活性很低", "B.胰岛素是降低合成代谢的激素", "C.胰岛素的作用与胰高血糖素相同", "D.胰岛素原从细胞分泌出来后再转变为胰岛素", "E.胰岛素是由A、B两条肽链通过盐键相连而构成的蛋白质"],
    "answer": "A"
  },
  {
    "id": 22,
    "question": "血浆胰岛素水平升高时靶细胞胰岛素受体发生的变化是",
    "options": ["A.数目升高", "B.数目减少", "C.作用增强", "D.亲和力改变", "E.数目没有改变"],
    "answer": "B"
  },
  {
    "id": 23,
    "question": "关于糖尿病分型的叙述，正确的是",
    "options": ["A.1型好发于20岁以上", "B.2型好发于20岁以下", "C.1型与HLA有关", "D.2型与HLA有关", "E.1型对胰岛素治疗不敏感"],
    "answer": "C"
  },
  {
    "id": 24,
    "question": "1型糖尿病常见的急性并发症是",
    "options": ["A.酮症酸中毒", "B.非酮症高渗性昏迷", "C.白内障", "D.动脉粥样硬化", "E.糖尿病肾病"],
    "answer": "A"
  },
  {
    "id": 25,
    "question": "2型糖尿病患者的特点是",
    "options": ["A.起病急", "B.治疗依赖胰岛素", "C.易发生酮症酸中毒", "D.自身抗体呈阴性", "E.在糖刺激后胰岛素呈快速释放"],
    "answer": "D"
  },
  {
    "id": 26,
    "question": "2型糖尿病早期患者的空腹胰岛素水平或其胰岛细胞状态可能为",
    "options": ["A.在糖刺激后胰岛素呈快速释放", "B.治疗依赖胰岛素", "C.正常或稍高", "D.胰岛素水平很低", "E.胰岛β细胞负荷较轻"],
    "answer": "C"
  },
  {
    "id": 27,
    "question": "可作为糖尿病患者过去6~8周血糖平均水平的定量指标是",
    "options": ["A.C肽", "B.胰岛素", "C.糖化血红蛋白", "D.糖化白蛋白", "E.随机血糖"],
    "answer": "C"
  },
  {
    "id": 28,
    "question": "关于糖化血红蛋白(GHb)的叙述，错误的是",
    "options": ["A.GHb是HbA与己糖缓慢并连续的非酶促反应产物", "B.GHb可用于早期糖尿病的诊断", "C.GHb形成量取决于血糖浓度和作用时间", "D.GHb可作为糖尿病长期监测的指标", "E.糖尿病病情控制后GHb浓度缓慢下降"],
    "answer": "B"
  },
  {
    "id": 29,
    "question": "关于糖化血红蛋白(GHb)的叙述，错误的是",
    "options": ["A.GHb 的浓度与红细胞寿命有关", "B.反映过去6~8周血糖平均水平", "C.反映过去2-3周血糖平均水平", "D.GHb不受每天葡萄糖波动的影响", "E.有溶血性疾病时GHb明显减少"],
    "answer": "C"
  },
  {
    "id": 30,
    "question": "反映2~3周前血糖平均水平的检查项目是",
    "options": ["A.C肽", "B.胰岛素", "C.糖化血红蛋白", "D.糖化白蛋白", "E.随机血糖"],
    "answer": "D"
  },
  {
    "id": 31,
    "question": "引发糖尿病患者并发白内障是由于",
    "options": ["A.糖异生增加", "B.糖原分解增加", "C.山梨醇途径增加", "D.醛糖还原酶增加", "E.磷酸戊糖途径增加"],
    "answer": "C"
  },
  {
    "id": 32,
    "question": "血浆葡萄糖测定的参考方法是",
    "options": ["A.己糖激酶法", "B.邻甲苯胺法", "C.脱氢酶法", "D.氧化酶-氧电极法", "E.氧化酶-过氧化物酶法"],
    "answer": "A"
  },
  {
    "id": 33,
    "question": "关于以胆固醇为原料合成的叙述，错误的是",
    "options": ["A.皮质醇", "B.雌二醇", "C.维生素D₃", "D.胆酸", "E.胆红素"],
    "answer": "E"
  },
  {
    "id": 34,
    "question": "HDL 中存在的主要载脂蛋白是",
    "options": ["A.ApoA I", "B.ApoB48", "C.ApoB100", "D.ApoC", "E.Apo(a)"],
    "answer": "A"
  },
  {
    "id": 35,
    "question": "血浆TG的合适水平是",
    "options": ["A.≤0.70 mmol/L", "B.≤1.70 mmol/L", "C.≤2.70 mmol/L", "D.≤3.70 mmol/L", "E.≤4.70 mmol/L"],
    "answer": "B"
  },
  {
    "id": 36,
    "question": "正常人空腹12h后一般不会出现",
    "options": ["A.FFA", "B.TC", "C.TG", "D.HDL-C", "E.CM"],
    "answer": "E"
  },
  {
    "id": 37,
    "question": "含有胆固醇最多的脂蛋白是",
    "options": ["A.CM", "B.LDL", "C.VLDL", "D.Lp(a)", "E.HDL"],
    "answer": "B"
  },
  {
    "id": 38,
    "question": "IIa型高脂蛋白血症外周血中以脂蛋白升高为主的是",
    "options": ["A.CM", "B.LDL", "C.VLDL", "D.Lp(a)", "E.HDL"],
    "answer": "B"
  },
  {
    "id": 39,
    "question": "关于清道夫受体的叙述，错误的是",
    "options": ["A.清道夫受体分布于胎盘、肝、脾等处的单核-巨噬细胞系统", "B.对氧化型 LDL具有高亲和力", "C.促使脂蛋白之间转移胆固醇", "D.是LDL 受体途径以外的脂质摄取途径", "E.受体具有跨膜结构域"],
    "answer": "C"
  },
  {
    "id": 40,
    "question": "脂蛋白电泳中前β脂蛋白是",
    "options": ["A.CM", "B.VLDL", "C.LDL", "D.HDL", "E.IDL"],
    "answer": "B"
  },
  {
    "id": 41,
    "question": "主要由遗传决定其血浆脂蛋白水平的是",
    "options": ["A.CM", "B.VLDL", "C.LDL", "D.HDL", "E.Lp(a)"],
    "answer": "E"
  },
  {
    "id": 42,
    "question": "血脂异常的治疗原则中的第一目标是",
    "options": ["A.降低VLDL浓度", "B.升高 HDL 浓度", "C.降低总胆固醇浓度", "D.降低LDL浓度", "E.降低甘油三酯浓度"],
    "answer": "D"
  },
  {
    "id": 43,
    "question": "关于载脂蛋白的叙述，错误的是",
    "options": ["A.构成并稳定脂蛋白的结构", "B.修饰并影响与脂蛋白代谢有关的酶的活性", "C.是脂蛋白表面的磷脂部分", "D.作为脂蛋白受体的配体", "E.脂蛋白中的蛋白质部分"],
    "answer": "C"
  },
  {
    "id": 44,
    "question": "血浆TC的合适水平是",
    "options": ["A.<3.18 mmol/L", "B.<4.18 mmol/L", "C.<5.18 mmol/L", "D.<6.18 mmol/L", "E.<7.18 mmol/L"],
    "answer": "C"
  },
  {
    "id": 45,
    "question": "我国健康成人血脂防治指南中，LDL-C的合适水平是",
    "options": ["A.<1.37 mmol/L", "B.<2.37 mmol/L", "C.<3.37 mmol/L", "D.<4.37 mmol/L", "E.<5.37 mmol/L"],
    "answer": "C"
  },
  {
    "id": 46,
    "question": "血浆中催化脂肪酰转移到胆固醇生成胆固醇酯的酶是",
    "options": ["A.LCAT", "B.ACAT", "C.磷脂酶", "D.肉毒碱脂肪酰转移酶", "E.脂肪酰转移酶"],
    "answer": "A"
  },
  {
    "id": 47,
    "question": "磷酸甘油氧化酶法测定血清甘油三酯时，其中苯酚及4-氨基安替比林是",
    "options": ["A.氧化剂", "B.还原剂", "C.显色剂", "D.催化剂", "E.皂化剂"],
    "answer": "C"
  },
  {
    "id": 48,
    "question": "血浆HDL-C的合适水平是",
    "options": ["A.≥1.04 mmol/L", "B.≥2.04 mmol/L", "C.≥3.04 mmol/L", "D.≥4.04 mmol/L", "E.≥5.04 mmol/L"],
    "answer": "A"
  },
  {
    "id": 49,
    "question": "关于血清 ApoAI、ApoB测定的叙述，错误的是",
    "options": ["A.目前已有 ApoAI、ApoB测定的决定性方法和参考方法", "B.应用5~7个不同浓度的定值血清,采用曲线拟合方式制备校准曲线", "C.对所用抗血清的要求是特异性好、高亲和力与高效价", "D.免疫透射比浊法是目前最常用的方法", "E.多用兔抗人或羊抗人多克隆抗体制备合适的抗血清"],
    "answer": "A"
  },
  {
    "id": 50,
    "question": "关于ApoAI是酶的辅因子的叙述,正确的是",
    "options": ["A.脂蛋白脂肪酶(LPL)", "B.肝脂酶(HL)", "C.卵磷脂胆固醇脂酰转移酶(LCAT)", "D.β-羟-β-甲戊二酸单酰辅酶A还原酶(HMG-CoA 还原酶)", "E.胆固醇酯转移蛋白(CETP)"],
    "answer": "C"
  },
  {
    "id": 51,
    "question": "琼脂糖凝胶电泳法分离脂蛋白的条带从负极到正极的顺序为",
    "options": ["A.CM、β脂蛋白、前β脂蛋白、α脂蛋白", "B.CM、前β脂蛋白、β脂蛋白、α脂蛋白", "C.α脂蛋白、β脂蛋白、前β脂蛋白、CM", "D.α脂蛋白、CM、前β脂蛋白、β脂蛋白", "E.α脂蛋白、前β脂蛋白、β脂蛋白、CM"],
    "answer": "A"
  },
  {
    "id": 52,
    "question": "禁食12h后,正常人血中的甘油三酯主要存在于",
    "options": ["A.VLDL", "B.HDL", "C.LDL", "D.IDL", "E.CM"],
    "answer": "A"
  },
  {
    "id": 53,
    "question": "含有蛋白质最多的脂蛋白是",
    "options": ["A.CM", "B.LDL", "C.VLDL", "D.Lp(a)", "E.HDL"],
    "answer": "E"
  },
  {
    "id": 54,
    "question": "血脂检测正确的做法是",
    "options": ["A.一次检查血中TC明显增加即可诊断为高胆固醇血症", "B.发现血脂或脂蛋白异常应间隔2周再复查一次,方能做出诊断", "C.血脂分析前应低脂饮食1周", "D.采集12-14h空腹血液检查", "E.静脉采血时止血带使用不超过1 min"],
    "answer": "D"
  },
  {
    "id": 55,
    "question": "密度最低的脂蛋白是",
    "options": ["A.CM", "B.LDL", "C.VLDL", "D.IDL", "E.HDL"],
    "answer": "A"
  },
  {
    "id": 56,
    "question": "富含TG的脂蛋白是",
    "options": ["A.CM和VLDL", "B.LDL 和HDL", "C.VLDL 和LDL", "D.Lp(a)和CM", "E.HDL和CM"],
    "answer": "A"
  },
  {
    "id": 57,
    "question": "关于HDL作用的叙述，错误的是",
    "options": ["A.限制动脉粥样硬化的发生与发展", "B.输送肝细胞外的过量CH进入肝脏后排泄", "C.抗氧化", "D.促进血浆中胆固醇酯化", "E.促进脂质通过肠壁的运输"],
    "answer": "E"
  },
  {
    "id": 58,
    "question": "关于血脂检测的叙述，错误的是",
    "options": ["A.血脂检测前1周尽量吃素食,多运动", "B.按危险因素的等级不同,血脂检测的时间间隔要求不同", "C.禁食12h后检测", "D.检测前不改变生活习惯(饮食结构、运动等)", "E.如果改变生活习惯,一般要求2-3个月后复查"],
    "answer": "A"
  },
  {
    "id": 59,
    "question": "血浆静置实验观察上层呈奶油状,下层透明,电泳原点处脂蛋白明显增多的是",
    "options": ["A.I型高脂血症", "B.II型高脂血症", "C.III型高脂血症", "D.IV型高脂血症", "E.V型高脂血症"],
    "answer": "A"
  },
  {
    "id": 60,
    "question": "激活 LPL的载脂蛋白是",
    "options": ["A.ApoA", "B.ApoB48", "C.ApoB100", "D.ApoC II", "E.Apo(a)"],
    "answer": "D"
  },
  {
    "id": 61,
    "question": "中间密度脂蛋白又称为",
    "options": ["A.CM 残粒", "B.LDL 残粒", "C.VLDL 残粒", "D.Lp(a)残粒", "E.HDL 残粒"],
    "answer": "C"
  },
  {
    "id": 62,
    "question": "运输内源性胆固醇的脂蛋白是",
    "options": ["A.CM", "B.LDL", "C.VLDL", "D.Lp(a)", "E.HDL"],
    "answer": "B"
  },
  {
    "id": 63,
    "question": "催化血浆中TG分解的关键酶是",
    "options": ["A.脂蛋白脂肪酶(LPL)", "B.肝脂酶(HL)", "C.卵磷脂胆固醇脂酰转移酶(LCAT)", "D.β-羟-β-甲戊二酸单酰辅酶A还原酶(HMG-CoA还原酶)", "E.胆固醇酯转移蛋白(CETP)"],
    "answer": "A"
  },
  {
    "id": 64,
    "question": "如血清甘油三酯浓度高于11.3mmol/L时,极易发生的并发症是",
    "options": ["A.甲亢", "B.脑梗死", "C.营养不良", "D.急性胰腺炎", "E.吸收不良综合征"],
    "answer": "D"
  },
  {
    "id": 65,
    "question": "能抑制纤溶酶活性的脂蛋白是",
    "options": ["A.VLDL", "B.LDL", "C.Lp(a)", "D.CM", "E.HDL"],
    "answer": "C"
  },
  {
    "id": 66,
    "question": "超速离心法分离脂蛋白,从试管底部到试管液面脂蛋白的次序依次为",
    "options": ["A.HDL、LDL、VLDL、CM", "B.HDL、VLDL、LDL、CM", "C.HDL、LDL、CM、VLDL", "D.CM、LDL、VLDL、HDL", "E.CM、VLDL、LDL、HDL"],
    "answer": "A"
  },
  {
    "id": 67,
    "question": "HDL-C测定的参考方法是",
    "options": ["A.聚乙烯硫酸沉淀法", "B.超速离心结合ALBK法", "C.电泳分离法", "D.磷钨酸镁沉淀法", "E.匀相测定法"],
    "answer": "B"
  },
  {
    "id": 68,
    "question": "根据国际生化学委员会的规定,酶的一个国际单位是指",
    "options": ["A.最适条件下,每小时催化生成 1 μmol 产物的酶量", "B.37°C下每分钟催化生成 1 μmol 产物的酶量", "C.25°C下,其他为最适条件,每分钟催化生成1μmol产物的酶量", "D.30°C下,每小时催化生成 1 μmol 产物的酶量", "E.在特定条件下,每分钟催化 1 μmol 底物产生变化所需的酶量"],
    "answer": "E"
  },
  {
    "id": 69,
    "question": "关于酶质量测定较酶活性测定的优点的叙述，错误的是",
    "options": ["A.灵敏度高", "B.特异性高", "C.易受抑制剂影响", "D.不受激活剂影响", "E.能测出不具活性的酶蛋白量"],
    "answer": "C"
  },
  {
    "id": 70,
    "question": "血清谷氨酰转肽酶(GGT)在人体组织细胞中含量最多的器官是",
    "options": ["A.肝脏", "B.肾脏", "C.心脏", "D.胰", "E.肠"],
    "answer": "B"
  },
  {
    "id": 71,
    "question": "关于血清酶活力测定的叙述，错误的是",
    "options": ["A.可测定产物生成量", "B.可测定底物的消耗量", "C.需要最适pH", "D.需要最适温度", "E.与底物浓度无关"],
    "answer": "E"
  },
  {
    "id": 72,
    "question": "人体内含AST活性最高的器官是",
    "options": ["A.肝脏", "B.脑", "C.心脏", "D.肾脏", "E.肠"],
    "answer": "C"
  },
  {
    "id": 73,
    "question": "心脏病变时,CK-MB/CK指数为",
    "options": ["A.<2%", "B.4%~25%", "C.>30%", "D.>40%", "E.>50%"],
    "answer": "B"
  },
  {
    "id": 74,
    "question": "关于酶活性和质量测定的叙述，错误的是",
    "options": ["A.测酶质量比测酶活性灵敏度高", "B.可以测到以前不易测定的酶", "C.免疫方法特异性低", "D.酶质量和酶活性存在不平行", "E.免疫方法测定同工酶简单方便"],
    "answer": "C"
  },
  {
    "id": 75,
    "question": "ALT与AST 比值最常用于鉴别",
    "options": ["A.病毒性肝炎与肝硬化", "B.肝硬化与脂肪肝", "C.病毒性肝炎与急性中毒性肝炎", "D.慢性活动性肝炎与慢性持续性肝炎", "E.梗阻性黄疸与溶血性黄疸"],
    "answer": "A"
  },
  {
    "id": 76,
    "question": "酶法测定血清三酰甘油中用到的酶有",
    "options": ["A.甘油激酶", "B.脂肪酶", "C.甘油磷酸氧化酶", "D.过氧化物酶", "E.以上都是"],
    "answer": "E"
  },
  {
    "id": 77,
    "question": "孕妇血清中酶活性增高最明显的是",
    "options": ["A.ALP", "B.ALT", "C.CHE", "D.CK", "E.LDH"],
    "answer": "A"
  },
  {
    "id": 78,
    "question": "血中影响酶清除快慢的主要因素是酶的",
    "options": ["A.分布", "B.数量", "C.运送", "D.半衰期", "E.质量"],
    "answer": "D"
  },
  {
    "id": 79,
    "question": "关于影响酶活性测定因素的叙述，错误的是",
    "options": ["A.底物浓度", "B.样品杯直径", "C.温度", "D.pH", "E.缓冲液的离子强度"],
    "answer": "B"
  },
  {
    "id": 80,
    "question": "关于用于标记的酶应符合的要求叙述，错误的是",
    "options": ["A.酶活性高", "B.具有可与抗原、抗体结合的基团", "C.具有可与生物素、亲和素结合的基团", "D.酶催化底物后的成色信号易判断", "E.纯度及比活性高"],
    "answer": "C"
  },
  {
    "id": 81,
    "question": "无论是化学法还是酶法测血清TG,最可能影响测定结果的物质是",
    "options": ["A.血清中的胆红素", "B.血清中的蛋白质", "C.血清中的葡萄糖", "D.血清中的游离甘油", "E.血清中的尿素"],
    "answer": "D"
  },
  {
    "id": 82,
    "question": "对嗜铬细胞瘤诊断特异性最高的是",
    "options": ["A.血浆E和NE测定", "B.尿E和NE测定", "C.VMA 测定", "D.胰高血糖素激发试验", "E.可乐定抑制试验"],
    "answer": "D"
  },
  {
    "id": 83,
    "question": "属于血浆特异酶的是",
    "options": ["A.胆碱酯酶", "B.脂肪酶", "C.转氨酶", "D.乳酸脱氢酶", "E.淀粉酶"],
    "answer": "A"
  },
  {
    "id": 84,
    "question": "关于影响细胞酶释放量的叙述，错误的是",
    "options": ["A.酶的组织分布", "B.细胞内外酶浓度的差异", "C.酶的相对分子量", "D.各种酶的测定波长及反应速率", "E.酶在细胞内的定位和存在形式"],
    "answer": "D"
  },
  {
    "id": 85,
    "question": "关于乳酸脱氢酶的叙述，错误的是",
    "options": ["A.细胞中LDH含量比血清高100倍", "B.标本宜存在4°C", "C.LDH 同工酶和CK-MB联合检测可用于助诊急性心肌梗死", "D.LDH有5种同工酶,每种同工酶最适反应条件不同", "E.LDH 主要存在于细胞质中"],
    "answer": "B"
  },
  {
    "id": 86,
    "question": "临床分析同工酶的方法是",
    "options": ["A.蛋白酶水解法", "B.沉淀法", "C.电泳法", "D.层析法", "E.热失活法"],
    "answer": "C"
  },
  {
    "id": 87,
    "question": "关于急性胰腺炎时血清胰蛋白酶的叙述，错误的是",
    "options": ["A.急性胰腺炎时,血清胰蛋白酶和淀粉酶平行升高,其峰值可达参考值上限的2-400倍", "B.两种胰蛋白酶的分布和急性胰腺炎的类型及严重程度有关", "C.轻型者80%~99%为游离胰蛋白酶原-1及极少的结合型胰蛋白酶原-1", "D.重型者游离胰蛋白酶原-1可低到胰蛋白酶总量的30%,大部分以结合形式存在", "E.胰蛋白酶原-1不可以与抗胰蛋白酶或α₂巨球蛋白结合"],
    "answer": "E"
  },
  {
    "id": 88,
    "question": "关于溶血性黄疸时胆红素代谢特点的叙述,正确的是",
    "options": ["A.血清结合胆红素明显升高", "B.尿胆红素强阳性", "C.尿胆原减少", "D.血清非结合胆红素明显升高", "E.尿胆素减少"],
    "answer": "D"
  },
  {
    "id": 89,
    "question": "肝损伤时,血清酶活性一般不升高的指标是",
    "options": ["A.ALT", "B.AST", "C.LDH", "D.AMY", "E.GGT"],
    "answer": "D"
  },
  {
    "id": 90,
    "question": "影响药物生物转化的主要器官是",
    "options": ["A.肝脏", "B.脾脏", "C.肾脏", "D.胃", "E.胰腺"],
    "answer": "A"
  },
  {
    "id": 91,
    "question": "不属于胆色素的化合物是",
    "options": ["A.胆素", "B.胆素原", "C.胆红素", "D.胆绿素", "E.血红素"],
    "answer": "E"
  },
  {
    "id": 92,
    "question": "反映肝功能不全的较敏感指标是",
    "options": ["A.白蛋白", "B.前白蛋白", "C.转铁蛋白", "D.β₂ 微球蛋白", "E.糖蛋白"],
    "answer": "B"
  },
  {
    "id": 93,
    "question": "关于溶血性黄疸特点的叙述,正确的是",
    "options": ["A.血中结合胆红素含量增高", "B.血中未结合胆红素浓度增高", "C.尿中胆红素增加", "D.粪便颜色变浅", "E.血中胆素原剧减"],
    "answer": "D"
  },
  {
    "id": 94,
    "question": "关于δ-胆红素的叙述，错误的是",
    "options": ["A.存在于高结合胆红素患者的血清中", "B.胆红素与白蛋白共价结合", "C.半衰期比白蛋白短", "D.分子量较胆红素大", "E.不易通过肾小球滤出"],
    "answer": "C"
  },
  {
    "id": 95,
    "question": "有助于鉴别原发性肝癌和良性肝病的是",
    "options": ["A.AFP-L1", "B.AFP-L2", "C.AFP-L3", "D.AFP-L4", "E.AFP-L5"],
    "answer": "C"
  },
  {
    "id": 96,
    "question": "ALT升高幅度大于AST升高幅度,最常见于",
    "options": ["A.急性肝炎", "B.慢性肝炎", "C.原发性肝癌", "D.肝硬化", "E.肝脓肿"],
    "answer": "A"
  },
  {
    "id": 97,
    "question": "血清胆红素测定的标本必须避免阳光直接照射以免结果减低,其原因是",
    "options": ["A.胆红素氧化成血红素", "B.胆红素氧化成胆黄素", "C.胆红素分解", "D.胆红素氧化成胆绿素", "E.间接胆红素变为直接血红素"],
    "answer": "D"
  },
  {
    "id": 98,
    "question": "生物转化过程中最重要的方式是",
    "options": ["A.使药物失效", "B.使生物活性物灭活", "C.使毒物毒性降低", "D.使非营养物质极性增加,利于排泄", "E.使某些药物药性更强或毒性增加"],
    "answer": "D"
  },
  {
    "id": 99,
    "question": "属于初级胆汁酸的是",
    "options": ["A.甘氨石胆酸", "B.甘氨胆酸", "C.牛磺脱氧胆酸", "D.牛磺石胆酸", "E.甘氨脱氧胆酸"],
    "answer": "B"
  },
  {
    "id": 100,
    "question": "属于次级胆汁酸的是",
    "options": ["A.甘氨鹅脱氧胆酸", "B.甘氨胆酸", "C.牛磺鹅脱氧胆酸", "D.脱氧胆酸", "E.牛磺胆酸"],
    "answer": "D"
  },
  {
    "id": 101,
    "question": "关于胆红素在血液中主要与血浆蛋白质结合而运输的叙述,正确的是",
    "options": ["A.γ球蛋白", "B.α₁球蛋白", "C.α₂球蛋白", "D.β球蛋白", "E.白蛋白"],
    "answer": "E"
  },
  {
    "id": 102,
    "question": "关于结合胆红素的叙述,正确的是",
    "options": ["A.主要是双葡萄糖醛酸胆红素", "B.与重复试剂呈间接反应", "C.水溶性小", "D.随正常人的尿液排出", "E.易透过生物膜"],
    "answer": "A"
  },
  {
    "id": 103,
    "question": "血中胆红素增加会在尿液中出现的胆红素是",
    "options": ["A.未结合胆红素", "B.结合胆红素", "C.肝前胆红素", "D.间接胆红素", "E.与白蛋白结合的胆红素"],
    "answer": "B"
  },
  {
    "id": 104,
    "question": "关于结合胆红素的叙述,正确的是",
    "options": ["A.Y蛋白", "B.葡萄糖酸", "C.胆汁酸", "D.6-磷酸葡萄糖", "E.葡萄糖醛酸"],
    "answer": "E"
  },
  {
    "id": 105,
    "question": "胆色素中无色的物质是",
    "options": ["A.直接胆红素", "B.间接胆红素", "C.胆色素原", "D.胆绿素", "E.尿胆素原"],
    "answer": "C"
  },
  {
    "id": 106,
    "question": "在胆汁中被排泄的胆汁酸在肠内通常变成",
    "options": ["A.结合胆红素", "B.尿胆原", "C.胆固醇", "D.未结合胆红素", "E.脱氧胆酸、石胆酸"],
    "answer": "E"
  },
  {
    "id": 107,
    "question": "血浆中出现LPX,可见于",
    "options": ["A.溶血性黄疸", "B.新生儿黄疸", "C.阻塞性黄疸", "D.急性肝坏死暴发性肝衰竭", "E.肝硬化性黄疸"],
    "answer": "C"
  },
  {
    "id": 108,
    "question": "正常人血中胆色素主要来源于",
    "options": ["A.胆汁", "B.胆汁酸盐", "C.衰老的红细胞", "D.还原酶", "E.氧化酶"],
    "answer": "C"
  },
  {
    "id": 109,
    "question": "肝脏清除胆固醇的主要方式是",
    "options": ["A.转变成类固醇", "B.转变成维生素", "C.合成 VLDL", "D.合成 LDL", "E.在肝细胞内转变成胆汁酸"],
    "answer": "E"
  },
  {
    "id": 110,
    "question": "关于致临床“胆红素脑病”的叙述,正确的是",
    "options": ["A.蛋白非结合型胆红素", "B.α组分胆红素(未结合胆红素)", "C.β组分胆红素(单葡萄糖醛酸结合胆红素)", "D.γ组分胆红素(双葡萄糖醛酸结合胆红素)", "E.δ组分胆红素(与血清白蛋白结合胆红素)"],
    "answer": "A"
  },
  {
    "id": 111,
    "question": "关于尿胆红素测定的叙述,正确的是",
    "options": ["A.正常人尿液中可阳性", "B.肝细胞性黄疸时尿胆红素增高", "C.阻塞性黄疸时尿胆红素阴性", "D.溶血性黄疸时尿胆红素明显增高", "E.严重肾损伤时尿胆红素明显增高"],
    "answer": "B"
  },
  {
    "id": 112,
    "question": "人体合成类固醇激素时的原料是",
    "options": ["A.甘油三酯", "B.胆固醇", "C.HDL", "D.ApoA", "E.ApoB"],
    "answer": "B"
  },
  {
    "id": 113,
    "question": "关于溶血性黄疸的叙述，错误的是",
    "options": ["A.血液中游离胆红素增加", "B.粪胆素原增加", "C.尿胆素原增加", "D.尿液中出现胆红素", "E.粪便颜色加深"],
    "answer": "D"
  },
  {
    "id": 114,
    "question": "关于摄取和转化胆红素的机制的叙述，错误的是",
    "options": ["A.肝细胞膜能结合某些阴离子", "B.肝细胞膜上存在特异载体系统", "C.肝细胞胞质中存在特异载体系统", "D.肝细胞能将胆红素转变成尿胆素原", "E.肝细胞能将胆红素转变成葡萄糖醛酸胆红素"],
    "answer": "C"
  },
  {
    "id": 115,
    "question": "肝脏“酶胆分离”的表现是",
    "options": ["A.血清ALT↑,血清胆红素↑", "B.血清ALT↑,血清胆红素↓", "C.血清ALT↓,血清胆红素↓", "D.血清ALT↓,血清胆红素↑", "E.血清AST↑,血清胆红素↑"],
    "answer": "D"
  },
  {
    "id": 116,
    "question": "肝癌实验室检查最有意义的项目是",
    "options": ["A.AFP", "B.GGT", "C.PT", "D.α岩藻糖苷酶", "E.CEA"],
    "answer": "A"
  },
  {
    "id": 117,
    "question": "关于血液中胆红素来源的叙述，错误的是",
    "options": ["A.血红蛋白", "B.胆汁酸", "C.肌红蛋白", "D.细胞色素", "E.过氧化物酶"],
    "answer": "B"
  },
  {
    "id": 118,
    "question": "正常人血清中的胆红素主要是",
    "options": ["A.结合胆红素", "B.未结合胆红素", "C.与球蛋白结合的胆红素", "D.与总蛋白结合的胆红素", "E.与钙结合的胆红素"],
    "answer": "B"
  },
  {
    "id": 119,
    "question": "肝细胞中与胆红素结合的主要物质是",
    "options": ["A.乙酰基", "B.硫酸根", "C.甲基", "D.葡萄糖醛酸", "E.甘氨酸"],
    "answer": "D"
  },
  {
    "id": 120,
    "question": "关于遗传代谢病的叙述，错误的是",
    "options": ["A.酶或蛋白质的基因发生突变是发病的根本原因", "B.缺陷的蛋白质往往是维持机体正常代谢所必需的酶类、膜蛋白或受体等", "C.对细胞和机体的代谢和功能影响严重,出现的病理和临床症状比较明显", "D.常导致早期夭折或终身残疾,对个体的危害非常严重", "E.单一病种的患病率不高,但总体发病率较高,没有根治方法"],
    "answer": "E"
  },
  {
    "id": 121,
    "question": "遗传代谢病病种繁多,根据异常代谢产物的分子大小分类,可分为小分子病和大分子病两大类,不属于大分子病的是",
    "options": ["A.溶酶体贮积症", "B.过氧化酶体病", "C.线粒体病", "D.氨基酸病", "E.黏多糖病"],
    "answer": "D"
  },
  {
    "id": 122,
    "question": "关于遗传代谢病基本特征的叙述，错误的是",
    "options": ["A.多在新生儿期、幼儿和儿童期发病,少数在成人期发病", "B.临床表现无特异性,多为神经系统、消化系统和呼吸系统症状", "C.常因饮食或应激因素而发病,一般起病急,症状重", "D.父母双方或一方携带有致病基因,家族史无同样病情的先证者存在", "E.预后差,是新生儿期和婴幼儿期的主要死亡原因之一"],
    "answer": "D"
  },
  {
    "id": 123,
    "question": "关于遗传代谢病治疗的叙述，错误的是",
    "options": ["A.通过低苯丙氨酸饮食治疗苯丙酮尿症", "B.甜菜碱治疗同型半胱氨酸血症及甲基丙二酸尿症", "C.骨髓移植治疗糖原贮积症Ⅰ型", "D.青霉胺、硫酸锌治疗肝豆状核变性", "E.基因治疗腺苷脱氨酶缺乏症"],
    "answer": "C"
  },
  {
    "id": 124,
    "question": "关于遗传代谢病预防的叙述，错误的是",
    "options": ["A.避免近亲结婚,减少隐性遗传病发生", "B.在人群中和患者亲属中筛查携带者", "C.显性遗传病患者要节育或绝育", "D.高危妊娠者进行产前诊断", "E.开展新生儿遗传代谢病筛查"],
    "answer": "C"
  },
  {
    "id": 125,
    "question": "造成苯丙酮尿症患儿体内苯丙氨酸积聚的原因是",
    "options": ["A.磷酸化酶缺陷", "B.酪氨酸缺乏", "C.体内铜蓝蛋白缺乏", "D.苯丙氨酸羟化酶缺陷或四氢生物喋呤缺乏", "E.磷酸化酶激酶缺乏"],
    "answer": "D"
  },
  {
    "id": 126,
    "question": "苯丙酮尿症最突出的临床特点是",
    "options": ["A.智力低下", "B.皮肤白皙", "C.肌张力减低", "D.头发黄褐色", "E.伴有惊厥"],
    "answer": "A"
  },
  {
    "id": 127,
    "question": "诊断儿童苯丙酮尿症最常用的筛选方法是",
    "options": ["A.血清苯丙氨酸浓度测定", "B.Guthrie 试验", "C.尿三氯化铁试验", "D.氨基酸层析法", "E.红细胞内的苯丙氨酸羟化酶活性测定"],
    "answer": "A"
  },
  {
    "id": 128,
    "question": "糖原累积症最常见的类型是",
    "options": ["A.I型", "B.II型", "C.III型", "D.V型", "E.VI型"],
    "answer": "A"
  },
  {
    "id": 129,
    "question": "肝豆状核变性的治疗方式是",
    "options": ["A.限制进食含铜高的食物", "B.应用青霉胺", "C.减少铜的摄入和增加铜的排出", "D.应用锌剂", "E.肝移植"],
    "answer": "C"
  },
  {
    "id": 130,
    "question": "关于先天性甲状腺功能减退的新生儿筛查的叙述，错误的是",
    "options": ["A.经皮采新生儿足后跟血,滴于特制的滤纸片上送检", "B.生后3天采血", "C.筛查测定血 T₃ 和 T₄", "D.筛查测定血 TSH", "E.阳性结果需再抽静脉血测定T3、T4、TSH进一步证实"],
    "answer": "C"
  },
  {
    "id": 131,
    "question": "糖原贮积症 I 型的发病机制是由于缺乏",
    "options": ["A.苯丙氨酸羟化酶", "B.葡萄糖-6-磷酸酶", "C.酪氨酸酶", "D.氨基己糖酶", "E.半乳糖-1-磷酸尿苷转移酶"],
    "answer": "B"
  },
  {
    "id": 132,
    "question": "家族性高胆固醇血症属于",
    "options": ["A.常染色体畸变", "B.常染色体显性遗传", "C.常染色体隐性遗传", "D.X连锁显性遗传", "E.X连锁隐性遗传"],
    "answer": "B"
  },
  {
    "id": 133,
    "question": "关于同型胱氨酸尿症的叙述，错误的是",
    "options": ["A.属于常染色体隐性遗传", "B.典型的症状见于胱硫醚合成酶缺乏型病例", "C.可用皮肤成纤维细胞测定胱硫醚合成酶的活性", "D.尿三氯化铁试验阳性", "E.N⁵, N¹⁰ 甲烯四氢叶酸还原酶缺乏也是发病机制之一"],
    "answer": "D"
  },
  {
    "id": 134,
    "question": "关于溶酶体病的叙述，错误的是",
    "options": ["A.属于常染色体显性遗传", "B.溶酶体储积症是人类最常见的遗传病之一", "C.大多数患者基因突变形成遗传复合体", "D.可通过检测绒毛细胞或培养的羊水细胞的酶活性进行产前诊断", "E.要通过检测血清中组织蛋白酶的活性作为诊断指标之一"],
    "answer": "A"
  },
  {
    "id": 135,
    "question": "关于线粒体病的叙述，错误的是",
    "options": ["A.线粒体病为线粒体中相关代谢酶类缺陷的一组异质性病变", "B.绝大多数线粒体病可影响多器官系统", "C.只由线粒体基因缺陷造成", "D.存在母系遗传、孟德尔遗传,或者两者均有", "E.任何年龄都可发生线粒体病"],
    "answer": "C"
  },
  {
    "id": 136,
    "question": "针对肾小球屏障功能,主要的检测对象是",
    "options": ["A.血液大分子蛋白质", "B.血液中分子蛋白质", "C.血液小分子蛋白质", "D.尿液大分子蛋白质", "E.尿液中小分子蛋白质"],
    "answer": "D"
  },
  {
    "id": 137,
    "question": "肾清除率中可作为肾小球滤过功能“金标准”的物质是",
    "options": ["A.菊粉", "B.葡萄糖", "C.对氨基马尿酸", "D.碘瑞特", "E.白蛋白"],
    "answer": "A"
  },
  {
    "id": 138,
    "question": "苦味酸与肌酐反应的时间“窗口期”是",
    "options": ["A.0~20s", "B.20~80 s", "C.80-120 s", "D.120-180s", "E.180~300 s"],
    "answer": "B"
  },
  {
    "id": 139,
    "question": "反映 GFR变化的理想内源性标志物是",
    "options": ["A.肌酐", "B.尿素", "C.胱抑素C", "D.菊粉", "E.β₂ 微球蛋白"],
    "answer": "C"
  },
  {
    "id": 140,
    "question": "当肾脏损伤较轻,出现以白蛋白为主的蛋白尿时,最可能的是",
    "options": ["A.选择性蛋白尿, SPI<0.1", "B.选择性蛋白尿, SPI>0.2", "C.非选择性蛋白尿, SPI<0.1", "D.非选择性蛋白尿, SPI>0.2", "E.非选择性蛋白尿, SPI=0.2"],
    "answer": "A"
  },
  {
    "id": 141,
    "question": "利用 Cer评估肾损伤程度时,尿毒症终末期的指征是",
    "options": ["A.≤10 mL/(min·1.73 m²)", "B.<25 mL/(min·1.73 m²)", "C.25~50 mL/(min·1.73 m²)", "D.50~80 mL/(min·1.73 m²)", "E.<80 mL/(min·1.73 m²)"],
    "answer": "A"
  },
  {
    "id": 142,
    "question": "正常人自由水清除率一般是",
    "options": ["A.负值,小于0", "B.等于0或接近于0", "C.正值,大于0", "D.2~3 mL/min", "E.4.4~61.6 mg/24 h"],
    "answer": "A"
  },
  {
    "id": 143,
    "question": "可用于鉴别 I 型和 II 型肾小管酸中毒的检验项目是",
    "options": ["A.氯化铵负荷试验", "B.HCO₃⁻ 负荷试验", "C.N-乙酰-β-D氨基葡萄糖苷酶", "D.中性粒细胞明胶酶相关脂质运载蛋白", "E.溶菌酶"],
    "answer": "B"
  },
  {
    "id": 144,
    "question": "肾小球功能检查中与GFR 良好线性关系的指标是",
    "options": ["A.血肌酐", "B.血尿素", "C.血 CysC", "D.尿微量 Alb", "E.血 β₂ 微球蛋白"],
    "answer": "C"
  },
  {
    "id": 145,
    "question": "早期肾小管损伤检查中最敏感特异的指标是",
    "options": ["A.PSP", "B.TmPAH", "C.NAG", "D.NGAL", "E.FeNa"],
    "answer": "D"
  },
  {
    "id": 146,
    "question": "检测值相对恒定、不易受尿量和饮食因素影响的物质是",
    "options": ["A.Alb", "B.脂质", "C.尿素", "D.Cr", "E.尿酸"],
    "answer": "B"
  },
  {
    "id": 147,
    "question": "体内生成尿酸的物质是",
    "options": ["A.葡萄糖", "B.Cr", "C.嘌呤核苷酸", "D.嘧啶核苷酸", "E.电解质"],
    "answer": "C"
  },
  {
    "id": 148,
    "question": "某物质经肾小球完全滤过后,由肾小管完全重吸收,则该物质的清除率是",
    "options": ["A.-100%", "B.0", "C.50%", "D.100%", "E.缺少数据,无法获知"],
    "answer": "B"
  },
  {
    "id": 149,
    "question": "肾病综合征患者出现低蛋白血症的主要原因是",
    "options": ["A.肾小球毛细血管壁通透性增加", "B.肾小管重吸收作用不足", "C.肝脏合成蛋白质能力减弱", "D.蛋白质代谢消耗异常", "E.外源性蛋白质摄入过低"],
    "answer": "A"
  },
  {
    "id": 150,
    "question": "男性确诊高尿酸血症的实验室诊断依据是",
    "options": ["A.血尿酸>420 µmol/L", "B.血尿酸 <380 µmol/L", "C.尿白蛋白排泄率 >200 µg/min", "D.血肌酐 >115 µmol/L", "E.尿素>21.4 mmol/L"],
    "answer": "A"
  },
  {
    "id": 151,
    "question": "临床可用于糖尿病肾病的早期诊断指标是",
    "options": ["A.FPG", "B.HbA1c", "C.UTP", "D.UmAlb", "E.Tf"],
    "answer": "D"
  },
  {
    "id": 152,
    "question": "脚气病缺乏的维生素是",
    "options": ["A.维生素A", "B.维生素B₁", "C.维生素 B₂", "D.维生素B₆", "E.维生素E"],
    "answer": "B"
  },
  {
    "id": 153,
    "question": "微量元素是指其含量少于人体总重量的",
    "options": ["A.1/100000", "B.1/10000", "C.1/1000", "D.1/100", "E.1/10"],
    "answer": "B"
  },
  {
    "id": 154,
    "question": "关于铁及其代谢的叙述,正确的是",
    "options": ["A.Fe²⁺比Fe³⁺溶解度小,故Fe³⁺不易吸收", "B.缺铁引起的贫血是巨细胞贫血", "C.铁在体内分两类,功能铁与贮存铁,功能铁占30%,贮存铁占70%", "D.转铁蛋白是衡量机体铁储存量比较准确的指标", "E.血清铁以Fe³⁺形式与转铁蛋白结合而运输"],
    "answer": "E"
  },
  {
    "id": 155,
    "question": "赖氨酰氧化酶参与胶原的形成,其催化活性发挥需要的微量元素是",
    "options": ["A.钼", "B.铝", "C.铜", "D.锰", "E.铅"],
    "answer": "C"
  },
  {
    "id": 156,
    "question": "关于肝豆状核变性与微量元素代谢异常有关的叙述,正确的是",
    "options": ["A.铜", "B.锌", "C.碘", "D.铁", "E.铝"],
    "answer": "A"
  },
  {
    "id": 157,
    "question": "谷胱甘肽过氧化物酶中含有的微量元素是",
    "options": ["A.铜", "B.硅", "C.锰", "D.碘", "E.硒"],
    "answer": "E"
  },
  {
    "id": 158,
    "question": "由胆固醇转化而来的是",
    "options": ["A.维生素A", "B.维生素 B₆", "C.维生素C", "D.维生素D", "E.维生素E"],
    "answer": "D"
  },
  {
    "id": 159,
    "question": "属于水溶性维生素的是",
    "options": ["A.视黄醇", "B.钙化醇", "C.维生素 B₆", "D.生育酚", "E.维生素K"],
    "answer": "C"
  },
  {
    "id": 160,
    "question": "具有抗氧化作用的脂溶性维生素是",
    "options": ["A.维生素K", "B.维生素E", "C.维生素D", "D.维生素C", "E.维生素A"],
    "answer": "B"
  },
  {
    "id": 161,
    "question": "葡萄糖耐量因子中含有微量元素的是",
    "options": ["A.铁", "B.铬", "C.钼", "D.锌", "E.钴"],
    "answer": "B"
  },
  {
    "id": 162,
    "question": "关于甲状腺素的生物学作用相关的微量元素的叙述,正确的是",
    "options": ["A.硒", "B.锰", "C.铜", "D.铁", "E.碘"],
    "answer": "E"
  },
  {
    "id": 163,
    "question": "肠病性肢端皮炎缺少的微量元素的是",
    "options": ["A.铁", "B.锰", "C.铜", "D.锌", "E.硒"],
    "answer": "D"
  },
  {
    "id": 164,
    "question": "关于铅的叙述,错误的是",
    "options": ["A.血清铅浓度0.965 µmol/L(200µg/L)属于相对安全水平", "B.铅中毒的危害主要表现在对神经系统、血液系统", "C.铅中毒会导致智力下降", "D.铅中毒会导致感觉功能障碍", "E.铅中毒可影响到生长发育"],
    "answer": "A"
  },
  {
    "id": 165,
    "question": "属人体必须微量元素的是",
    "options": ["A.锌、氟、硒、镁、钼", "B.钴、镍、硅、铅、铜", "C.碘、铜、锌、锰、铁", "D.钒、铬、铁、锌、钾", "E.氟、碘、铜、铝、钴"],
    "answer": "C"
  },{
    "id": 166,
    "question": "属有害微量元素的是",
    "options": ["A.硼", "B.锌", "C.汞", "D.镍", "E.氟"],
    "answer": "C"
  },
  {
    "id": 167,
    "question": "与凝血酶原生成有关的维生素是",
    "options": ["A.维生素A", "B.维生素C", "C.维生素D", "D.维生素E", "E.维生素K"],
    "answer": "E"
  },
  {
    "id": 168,
    "question": "可作为呼吸困难的慢性心力衰竭和肺部疾病鉴别指标的是",
    "options": ["A.心肌肌钙蛋白T", "B.心肌肌钙蛋白I", "C.肌红蛋白", "D.心型脂肪酸结合蛋白", "E.B型利钠肽及B型利钠肽原N端肽"],
    "answer": "E"
  },
  {
    "id": 169,
    "question": "诊断 AMI的确定性标志物是",
    "options": ["A.cTnT", "B.cTnI", "C.Mb", "D.CK-MB", "E.HFABP"],
    "answer": "A"
  },
  {
    "id": 170,
    "question": "在胸痛发作2~12h为阴性可排除急性心肌梗死,阴性预测值价值为100%的指标是",
    "options": ["A.cTnT", "B.cTnI", "C.Mb", "D.CK-MB", "E.HFABP"],
    "answer": "C"
  },
  {
    "id": 171,
    "question": "关于肌钙蛋白评估的叙述，错误的是",
    "options": ["A.特异性和敏感度高于CK", "B.能检测微小的心肌损伤", "C.双峰的出现,易于判断再灌注成功与否", "D.cTn用于诊断近期发生再梗死效果最好", "E.在心肌损伤6小时内敏感性较低"],
    "answer": "D"
  },
  {
    "id": 172,
    "question": "关于传统心肌酶谱检测指标的叙述，错误的是",
    "options": ["A.CK-MB", "B.CK-MM", "C.LDH", "D.Mb", "E.AST"],
    "answer": "B"
  },
  {
    "id": 173,
    "question": "诊断心力衰竭单个最佳的标志物是",
    "options": ["A.ANP", "B.HFABP", "C.BNP", "D.Mb", "E.cTnT"],
    "answer": "C"
  },
  {
    "id": 174,
    "question": "关于心血管疾病的生物化学检测指标的叙述，错误的是",
    "options": ["A.cTnT", "B.cTnI", "C.Mb", "D.HFABP", "E.Hb"],
    "answer": "E"
  },
  {
    "id": 175,
    "question": "若总CK>200 U/L, CK-MB在4%~25%,可考虑",
    "options": ["A.肌肉疾病", "B.AMI", "C.HF", "D.心肌炎", "E.ACS"],
    "answer": "B"
  },
  {
    "id": 176,
    "question": "关于 cTnT 在心血疾病的诊断中应用的叙述，错误的是",
    "options": ["A.诊断 AMI", "B.判断微小型肌损伤", "C.诊断 HF", "D.评估溶栓疗法是否成功", "E.用于判断心肌梗死面积的大小"],
    "answer": "C"
  },
  {
    "id": 177,
    "question": "可用于区分心肌损伤及骨骼肌损伤的是",
    "options": ["A.LDH1/LDH2", "B.AST/ALT", "C.cTnT/cTnI", "D.Mb/HFABP", "E.Mb/BNP"],
    "answer": "D"
  },
  {
    "id": 178,
    "question": "关于高血压实验室检查的叙述，错误的是",
    "options": ["A.明确血压异常升高的病因", "B.鉴别原发性与继发性高血压", "C.明确高血压病情严重程度", "D.明确同型半胱氨酸是否升高", "E.明确是否存在并发症"],
    "answer": "D"
  },
  {
    "id": 179,
    "question": "具有抗动脉粥样硬化的脂蛋白是",
    "options": ["A.HDL", "B.LDL", "C.CM", "D.VLDL", "E.IDL"],
    "answer": "A"
  },
  {
    "id": 180,
    "question": "关于反映心肌损伤的理想生物标志物应具备的特点的叙述，错误的是",
    "options": ["A.具有高度的心脏特异性", "B.心肌损伤后浓度迅速升高", "C.检测方法简便迅速", "D.在心肌和血液中含量最高", "E.应用价值已由临床证实"],
    "answer": "D"
  },
  {
    "id": 181,
    "question": "肌酸激酶含量最高的是",
    "options": ["A.骨骼肌", "B.脑组织", "C.红细胞", "D.肝", "E.心肌"],
    "answer": "A"
  },
  {
    "id": 182,
    "question": "急性心肌梗死发生后机体最先恢复正常水平的酶是",
    "options": ["A.AST", "B.ALT", "C.ALP", "D.LDH", "E.CK-MB"],
    "answer": "E"
  },
  {
    "id": 183,
    "question": "关于肌钙蛋白的叙述，错误的是",
    "options": ["A.肌钙蛋白用于诊断近期发生再梗死效果很差", "B.肌钙蛋白用于诊断近期发生再梗死效果最好", "C.肌钙蛋白敏感度高于CK", "D.肌钙蛋白可用于评估病情的轻重和再灌注是否成功", "E.窗口期长,有利于诊断迟发的AMI"],
    "answer": "B"
  },
  {
    "id": 184,
    "question": "用于急性冠状动脉综合征实验室诊断的心肌肌钙蛋白是",
    "options": ["A.cTnT和MB", "B.cTnI 和cTnT", "C.cTnI 和 TnC", "D.cTnT和TnC", "E.cTnT 和Hb"],
    "answer": "B"
  },
  {
    "id": 185,
    "question": "关于BNP的叙述，错误的是",
    "options": ["A.BNP 具有很高的阴性预测价值,BNP正常可排除心力衰竭", "B.BNP 是由心和脑分泌的一种多肽,具有排钠利尿和扩张血管的功能", "C.BNP和NT-proBNP 等摩尔释放入血", "D.BNP 随年龄正增变化水平检测临界值明显升高", "E.BNP 的半衰期约为22 min"],
    "answer": "D"
  },
  {
    "id": 186,
    "question": "分泌内因子的是",
    "options": ["A.胃壁细胞", "B.黏膜上皮细胞", "C.腺体", "D.胃腺", "E.主细胞"],
    "answer": "A"
  },
  {
    "id": 187,
    "question": "引起卓-艾综合征的是",
    "options": ["A.胰岛素瘤", "B.促胃泌素瘤", "C.PP瘤", "D.类癌", "E.生长抑制瘤"],
    "answer": "B"
  },
  {
    "id": 188,
    "question": "胃内 Hp 感染可引起",
    "options": ["A.胃液尿素减少或缺如", "B.前列腺素合成增多", "C.胃蛋白酶活性增高", "D.胃泌素分泌显著增多", "E.胃酸分泌减少"],
    "answer": "A"
  },
  {
    "id": 189,
    "question": "可抑制胃酸、胃蛋白酶和胃液分泌的是",
    "options": ["A.小促胃液素", "B.促胰激素", "C.缩胆囊素", "D.抑胃肽", "E.血管活性肠肽"],
    "answer": "D"
  },
  {
    "id": 190,
    "question": "关于卓-艾综合征的临床表现的叙述，错误的是",
    "options": ["A.高促胃液素血症", "B.胃酸分泌减少", "C.反复再发十二指肠溃疡", "D.腹泻", "E.脂肪泻"],
    "answer": "B"
  },
  {
    "id": 191,
    "question": "关于血清胃泌素水平增高的叙述，错误的是",
    "options": ["A.恶性贫血", "B.珠蛋白生成障碍性贫血", "C.胃萎缩性病变", "D.卓-艾综合征", "E.肾衰竭"],
    "answer": "B"
  },
  {
    "id": 192,
    "question": "关于胰腺可分泌消化酶的叙述，错误的是",
    "options": ["A.糖类消化酶", "B.蛋白消化酶", "C.脂肪水解酶", "D.核酸水解酶", "E.转氨酶"],
    "answer": "E"
  },
  {
    "id": 193,
    "question": "胃液中可保护胃黏膜不受胃蛋白酶消化分解的成分是",
    "options": ["A.盐酸", "B.内因子", "C.乙酰胆碱", "D.组胺", "E.黏液"],
    "answer": "E"
  },
  {
    "id": 194,
    "question": "急性胰腺炎患者在急性发作时,尿中淀粉酶活性增高出现于",
    "options": ["A.2~6h", "B.6-10h", "C.24-28 h", "D.30~36h", "E.12-24h"],
    "answer": "E"
  },
  {
    "id": 195,
    "question": "关于脂肪酶的叙述，错误的是",
    "options": ["A.脂肪酶活性升高与淀粉酶基本平行,但特异性大于淀粉酶", "B.脂肪酶活性升高与淀粉酶基本平行,但特异性小于淀粉酶", "C.可用于急性胰腺炎后期的诊断", "D.在急性胰腺炎病程中持续升高的时间比淀粉酶长", "E.腮腺炎伴发腹痛时,只表现为淀粉酶升高而脂肪酶正常,可用脂肪酶做鉴别诊断"],
    "answer": "B"
  },
  {
    "id": 196,
    "question": "关于胰外分泌功能试验的叙述，错误的是",
    "options": ["A.NBT-PABA 试验", "B.胰多肽试验", "C.促胰液素试验", "D.Lundh 试验", "E.胰液淀粉酶测定"],
    "answer": "E"
  },
  {
    "id": 197,
    "question": "检测胃泌素常用的方法是",
    "options": ["A.ELISA法", "B.酶联免疫法", "C.放射免疫法", "D.化学发光免疫法", "E.琼脂糖凝胶电泳法"],
    "answer": "C"
  },
  {
    "id": 198,
    "question": "关于血清胃泌素测定的叙述，错误的是",
    "options": ["A.是诊断卓-艾综合征较为特异和可靠的方法", "B.诊断时须达500ng/L或以上方可", "C.如果同时有高胃泌素血症和高胃酸分泌,则高度提示卓-艾综合征", "D.血清胃泌素正常而临床上又怀疑卓-艾综合征者可行激发试验", "E.B型萎缩性胃炎可见胃泌素升高"],
    "answer": "E"
  },
  {
    "id": 199,
    "question": "检测胰腺外分泌功能试验的是",
    "options": ["A.菊粉清除试验", "B.内生肌酐清除试验", "C.NBT-对氨基苯甲酸试验", "D.促胰酶素-促胰液素试验", "E.对氨基马尿酸清除率"],
    "answer": "C"
  },
  {
    "id": 200,
    "question": "关于胰腺的外分泌功能试验的叙述，错误的是",
    "options": ["A.分为直接和间接试验", "B.主要用于诊断慢性胰腺炎和胰腺癌", "C.直接试验通过十二指肠插管收集胰液进行分析", "D.间接试验用试餐刺激胰腺分泌", "E.直接试验较间接试验简便易行"],
    "answer": "E"
  },
  {
    "id": 201,
    "question": "胰腺炎时的酶学检测有",
    "options": ["A.淀粉酶、脂肪酶、磷脂酶A1", "B.淀粉酶、脂肪酶、尿胰蛋白酶原Ⅱ", "C.麦芽糖酶、脂肪酶、胰蛋白酶", "D.麦芽糖酶、脂肪酶、谷氨酰转肽酶", "E.淀粉酶、脂肪酶、弹性蛋白酶"],
    "answer": "B"
  },
  {
    "id": 202,
    "question": "血钙的参考区间为",
    "options": ["A.2.25-2.75 mmol/L", "B.3.5~5.5 mmol/L", "C.3.61~6.11 mmol/L", "D.95~110 mmol/L", "E.135~145 mmol/L"],
    "answer": "A"
  },
  {
    "id": 203,
    "question": "关于血钙的叙述，错误的是",
    "options": ["A.血钙浓度过低可引起抽搐", "B.低钙可引起佝偻病", "C.血钙受甲状腺素调节", "D.可采用偶氮砷法测定血钙", "E.恶性肿瘤骨转移是引起血钙升高的常见原因"],
    "answer": "C"
  },
  {
    "id": 204,
    "question": "测定血中磷浓度时,会造成结果偏高的是",
    "options": ["A.溶血", "B.饭后采血", "C.经期采血", "D.静脉注射胰岛素", "E.静脉注射肾上腺素"],
    "answer": "A"
  },
  {
    "id": 205,
    "question": "关于高钙血症常见病因的叙述，错误的是",
    "options": ["A.恶性肿瘤", "B.原发性甲状旁腺功能亢进", "C.维生素D中毒", "D.甲亢", "E.急性胰腺炎"],
    "answer": "E"
  },
  {
    "id": 206,
    "question": "可调节体内钙代谢的是",
    "options": ["A.胰岛素", "B.降钙素", "C.肾上腺皮质激素", "D.维生素C", "E.维生素A"],
    "answer": "B"
  },
  {
    "id": 207,
    "question": "1,25(OH)2-D3的生理作用是",
    "options": ["A.使血钙升高,血磷降低", "B.使血钙降低,血磷升高", "C.使血钙、血磷均降低", "D.使血钙、血磷均升高", "E.对血钙、血磷浓度无明显影响"],
    "answer": "D"
  },
  {
    "id": 208,
    "question": "可促进 1,25-(OH)2-D3 合成的是",
    "options": ["A.血磷增高", "B.血钙增高", "C.PTH分泌增多", "D.降钙素分泌增多", "E.雄激素分泌增多"],
    "answer": "C"
  },
  {
    "id": 209,
    "question": "1,25(OH)2-D3 对骨盐的作用是",
    "options": ["A.仅促进骨质钙化", "B.促进骨质钙化,抑制骨钙游离", "C.促进骨钙游离,抑制骨质钙化", "D.既促进骨质钙化,又促进骨钙游离", "E.既抑制骨质钙化,又抑制骨钙游离"],
    "answer": "D"
  },
  {
    "id": 210,
    "question": "调节 1,25-(OH)2-D3 合成的关键酶是",
    "options": ["A.25-羟化酶", "B.24-羟化酶", "C.7-羟化酶", "D.1-羟化酶", "E.1,25-羟化酶"],
    "answer": "D"
  },
  {
    "id": 211,
    "question": "可导致神经肌肉兴奋性增加,出现手足抽搐的是",
    "options": ["A.血浆[H+] ↑", "B.血浆[Ca2+] ↑", "C.血浆[K+]↑", "D.血浆[Ca2+] ↓", "E.血浆[K+] ↓"],
    "answer": "D"
  },
  {
    "id": 212,
    "question": "维持血浆钙、磷含量相对恒定的重要环节是",
    "options": ["A.足量的维生素D供应", "B.足量的PTH分泌", "C.钙盐在骨中沉积", "D.骨中钙盐溶解", "E.成骨与溶骨作用保持动态平衡"],
    "answer": "E"
  },
  {
    "id": 213,
    "question": "关于钙、磷的叙述，错误的是",
    "options": ["A.钙盐和磷酸盐是人体内含量最高的无机盐", "B.降钙素可减低血钙", "C.维生素D对钙磷代谢有重要作用,它仅由食物中摄取并转化为活性形式", "D.食物中的钙、磷比例为2:1时最利于机体吸收", "E.甲亢时血钙也可见升高"],
    "answer": "C"
  },
  {
    "id": 214,
    "question": "降钙素对钙磷代谢的影响是",
    "options": ["A.使尿磷增加,血磷降低", "B.使尿磷减少,血磷升高", "C.使尿钙减少,血钙升高", "D.促进溶骨作用", "E.生理浓度即可促进肠道对钙的吸收"],
    "answer": "A"
  },
  {
    "id": 215,
    "question": "引起手足抽搐的原因是血浆中",
    "options": ["A.结合钙浓度降低", "B.结合钙浓度升高", "C.离子钙浓度升高", "D.离子钙浓度降低", "E.离子钙浓度升高,结合钙浓度降低"],
    "answer": "D"
  },
  {
    "id": 216,
    "question": "促进骨盐溶解最主要的激素是",
    "options": ["A.降钙素", "B.甲状旁腺激素", "C.甲状腺素", "D.雌激素", "E.维生素D"],
    "answer": "B"
  },
  {
    "id": 217,
    "question": "测定血中磷浓度时,可造成结果偏高的是",
    "options": ["A.溶血", "B.饭后采血", "C.经期采血", "D.静脉注射胰岛素", "E.静脉注射肾上腺素"],
    "answer": "A"
  },
  {
    "id": 218,
    "question": "幼儿期生长激素分泌不足可引起",
    "options": ["A.呆小症", "B.克汀病", "C.侏儒症", "D.闭经一泌乳综合征", "E.肢端肥大症"],
    "answer": "C"
  },
  {
    "id": 219,
    "question": "关于血清甲状腺素的描述，正确的是",
    "options": ["A.T3 的量远比 T4 多", "B.T4 的活性大于 T3", "C.T4 的量比 T3 多", "D.T4 的生理活性等于 T3", "E.T3 的量和 T4 一样多"],
    "answer": "C"
  },
  {
    "id": 220,
    "question": "T3的主要来源是",
    "options": ["A.两个DIT 聚合而成", "B.两个MIT 聚合而成", "C.一个DIT和一个MIT聚合而成", "D.T4 在5位上脱碘而成", "E.T4 在5'位上脱碘而成"],
    "answer": "E"
  },
  {
    "id": 221,
    "question": "血浆中 T3 和 T4 含量增加时可反馈抑制",
    "options": ["A.ACTH分泌", "B.FSH分泌", "C.LH分泌", "D.PRL分泌", "E.TRH分泌"],
    "answer": "E"
  },
  {
    "id": 222,
    "question": "继发性甲减时出现的甲状腺激素类指标变化为",
    "options": ["A.T3、T4 ↑, TSH↓", "B.T4 ↓, TSH ↑", "C.T3 ↓, T4 ↓, TSH↓", "D.T3 ↑, T4 ↑, TSH ↑", "E.T3 ↑, T4 ↑, TSH 不变"],
    "answer": "C"
  },
  {
    "id": 223,
    "question": "生长发育期GH过度分泌会导致",
    "options": ["A.侏儒症", "B.巨人症", "C.库欣综合征", "D.肢端肥大症", "E.艾迪生病"],
    "answer": "B"
  },
  {
    "id": 224,
    "question": "由腺垂体分泌的激素是",
    "options": ["A.抗利尿激素", "B.缩宫素", "C.生长激素", "D.甲状腺激素", "E.肾上腺激素"],
    "answer": "C"
  },
  {
    "id": 225,
    "question": "血液中甲状腺激素与血浆蛋白结合的是",
    "options": ["A.白蛋白", "B.前白蛋白", "C.血清甲状腺素结合球蛋白", "D.甲状腺球蛋白", "E.转铁蛋白"],
    "answer": "C"
  },
  {
    "id": 226,
    "question": "甲状腺功能紊乱筛查的首选项目是",
    "options": ["A.TT3", "B.TT4", "C.FT3", "D.FT4", "E.TSH"],
    "answer": "E"
  },
  {
    "id": 227,
    "question": "关于库欣综合征表现的叙述，错误的是",
    "options": ["A.皮质醇分泌物昼夜节律", "B.痤疮", "C.向心性肥胖", "D.肾上腺髓质肿瘤", "E.皮肤紫纹"],
    "answer": "D"
  },
  {
    "id": 228,
    "question": "通过细胞内受体发挥作用的激素是",
    "options": ["A.类固醇类激素", "B.氨基酸衍生物类激素", "C.蛋白质类激素", "D.肽类激素", "E.脂肪酸衍生物"],
    "answer": "A"
  },
  {
    "id": 229,
    "question": "下丘脑产生可调节ACTH分泌的激素是",
    "options": ["A.TRH", "B.GRH", "C.GHRH", "D.GHIH", "E.CRH"],
    "answer": "B"
  },
  {
    "id": 230,
    "question": "反映慢性生长激素过度分泌的最有效指标的是",
    "options": ["A.GH", "B.IGF-1", "C.GHRH", "D.GHIH", "E.ACTH"],
    "answer": "B"
  },
  {
    "id": 231,
    "question": "甲亢时升高最有诊断意义的是",
    "options": ["A.TT3", "B.TT4", "C.FT3", "D.FT4", "E.rT3"],
    "answer": "C"
  },
  {
    "id": 232,
    "question": "原发性甲减是指",
    "options": ["A.由于下丘脑或垂体疾病所致", "B.由于甲状腺本身疾病所致", "C.由于下丘脑疾病所致", "D.由于甲状腺对TSH 有抵抗", "E.由于靶组织对TH不敏感"],
    "answer": "B"
  },
  {
    "id": 233,
    "question": "rT3的主要来源是",
    "options": ["A.两个DIT 聚合而成", "B.两个MIT聚合而成", "C.一个DIT 和一个MIT聚合而成", "D.T4 在5位上脱碘而成", "E.T4 在5'位上脱碘而成"],
    "answer": "D"
  },
  {
    "id": 234,
    "question": "继发性甲亢时出现的甲状腺激素类指标变化为",
    "options": ["A.T3、T4 ↑, TSH↓", "B.T3 ↓, TSH↑", "C.T3 ↓, T4 ↓, TSH↓", "D.T3、T4 ↑, TSH ↑", "E.T3、T4↑, TSH 不变"],
    "answer": "D"
  },
  {
    "id": 235,
    "question": "原发性甲亢时出现的甲状腺激素类指标变化为",
    "options": ["A.T3、T4 ↑, TSH↓", "B.T4 ↓, TSH ↑", "C.T4 ↓, TSH↓", "D.T3、T4↑, TSH↑", "E.T3、T4 ↑, TSH 不变"],
    "answer": "A"
  },
  {
    "id": 236,
    "question": "原发性甲减时出现的甲状腺激素类指标变化为",
    "options": ["A.T3、T4 ↑, TSH↓", "B.T4 ↓, TSH ↑", "C.T4 ↓, TSH↓", "D.T3、T4 ↑, TSH ↑", "E.T3 ↑,TSH不变"],
    "answer": "B"
  },
  {
    "id": 237,
    "question": "关于下丘脑-垂体功能检查项目的叙述，错误的是",
    "options": ["A.血清甲状腺素结合球蛋白", "B.生长激素", "C.催乳素", "D.促性腺激素", "E.促黄体素"],
    "answer": "A"
  },
  {
    "id": 238,
    "question": "作为甲状腺功能紊乱的首选筛查项目的是",
    "options": ["A.T3", "B.T4", "C.PTH", "D.rT3", "E.TSH"],
    "answer": "E"
  },
  {
    "id": 239,
    "question": "关于内分泌系统的叙述，正确的是",
    "options": ["A.区别于外分泌腺的系统", "B.由内分泌腺及全身内分泌细胞组成的信息传递系统", "C.无导管,分泌物直接进入血液的腺体", "D.分泌物通过体液传递信息的系统", "E.都通过下丘脑-腺垂体-内分泌腺(细胞)-激素系统的反馈调节"],
    "answer": "B"
  },
  {
    "id": 240,
    "question": "关于生物活性物质的叙述，错误的是",
    "options": ["A.肾上腺素", "B.胰岛素", "C.内因子", "D.前列腺素", "E.甲状腺素"],
    "answer": "C"
  },
  {
    "id": 241,
    "question": "关于含氮激素的叙述，错误的是",
    "options": ["A.生长激素", "B.催乳素", "C.促甲状腺激素释放激素", "D.雄激素", "E.抗利尿激素"],
    "answer": "D"
  },
  {
    "id": 242,
    "question": "血中激素浓度极低,但生理作用非常明显,这是因为",
    "options": ["A.激素的半衰期很长", "B.激素的特异性很高", "C.激素分泌的持续时间很长", "D.细胞内存在高效能的生物放大系统", "E.与血浆蛋白结合率低"],
    "answer": "D"
  },
  {
    "id": 243,
    "question": "下丘脑-腺垂体调节激素的分泌调控,主要受其调节的内分泌靶腺(细胞)释放的激素水平长反馈调节,主要作用于腺垂体的激素是",
    "options": ["A.皮质醇", "B.甲状腺激素", "C.雌二醇", "D.醛固酮", "E.生长激素"],
    "answer": "B"
  },
  {
    "id": 244,
    "question": "儿童 GH过度分泌会导致",
    "options": ["A.侏儒症", "B.巨人症", "C.肢端肥大症", "D.库欣综合征", "E.艾迪生病"],
    "answer": "B"
  },
  {
    "id": 245,
    "question": "甲状腺素是一种含碘的",
    "options": ["A.儿茶酚胺", "B.多肽", "C.脂肪酸衍生物", "D.氨基酸衍生物", "E.核苷酸"],
    "answer": "D"
  },
  {
    "id": 246,
    "question": "合成甲状腺激素的物质是",
    "options": ["A.甲状腺球蛋白分子中的酪氨酸残基", "B.甲状腺球蛋白分子中的色氨酸残基", "C.游离存在的酪氨酸", "D.游离存在的色氨酸", "E.甲状腺素结合球蛋白"],
    "answer": "A"
  },
  {
    "id": 247,
    "question": "无结构的类似性的多肽激素是",
    "options": ["A.TSH", "B.LH", "C.FSH", "D.hCG", "E.GC"],
    "answer": "E"
  },
  {
    "id": 248,
    "question": "血液中最重要的缓冲系统是",
    "options": ["A.血红蛋白缓冲系统", "B.磷酸氢二钠-磷酸二氢钠缓冲系统", "C.碳酸盐-碳酸缓冲系统", "D.血浆蛋白的缓冲系统", "E.血浆内有机酸缓冲体系"],
    "answer": "C"
  },
  {
    "id": 249,
    "question": "关于电解质的叙述，正确的是",
    "options": ["A.体液中阴阳离子摩尔数相等", "B.体液中阴阳离子总当量数相等", "C.细胞内外电解质摩尔数相等", "D.细胞内外电解质当量数相等", "E.细胞内外阴阳离子摩尔数相等"],
    "answer": "B"
  },
  {
    "id": 250,
    "question": "在pH 7.4的碳酸盐碳酸缓冲系统中, [HCO3-]/[H2CO3] 的值是",
    "options": ["A.1:20", "B.1:10", "C.20:1", "D.10:1", "E.5:1"],
    "answer": "C"
  },
  {
    "id": 251,
    "question": "钾、钠和氯离子的主要排泄器官是",
    "options": ["A.皮肤", "B.肠道", "C.肝", "D.肾", "E.肺"],
    "answer": "D"
  },
  {
    "id": 252,
    "question": "关于血钾测定的叙述，正确的是",
    "options": ["A.血浆和血清钾的结果无明显差别", "B.全血标本冷藏后测定血钾对结果的影响可以忽略不计", "C.低钾血症是指血钾浓度低于 1.0 mmol/L 的一种病理状态", "D.酸中毒时血钾浓度偏低", "E.全血标本放置室温会导致测定结果偏低"],
    "answer": "E"
  },
  {
    "id": 253,
    "question": "血气分析标本使用的抗凝剂应为",
    "options": ["A.枸橼酸钠", "B.草酸钠", "C.氟化钠", "D.肝素", "E.EDTA - Na2"],
    "answer": "D"
  },
  {
    "id": 254,
    "question": "电解质分析的标本冷藏数天后测定会引起",
    "options": ["A.血清钾升高", "B.血清钾降低", "C.血清钠升高", "D.血清钠降低", "E.血清氯升高"],
    "answer": "A"
  },
  {
    "id": 255,
    "question": "使细胞内钾向细胞外转移引起高血钾症的是",
    "options": ["A.急性肾功能不全", "B.代谢性酸中毒", "C.代谢性碱中毒", "D.严重呕吐、腹泻", "E.肾上腺皮质激素长期使用"],
    "answer": "B"
  },
  {
    "id": 256,
    "question": "单纯性代谢性酸中毒时",
    "options": ["A.AB>SB", "B.AB<SB", "C.AB ↑=SB ↑", "D.AB ↓=SB ↓", "E.AG肯定升高"],
    "answer": "D"
  },
  {
    "id": 257,
    "question": "代谢性酸碱平衡原发性变化的指标是",
    "options": ["A.pH", "B.PaO2", "C.PaCO2", "D.TCO2", "E.HCO3-"],
    "answer": "E"
  },
  {
    "id": 258,
    "question": "血气分析中表示呼吸性酸碱平衡的指标是",
    "options": ["A.pH", "B.PaO2", "C.PaCO2", "D.TCO2", "E.HCO3-"],
    "answer": "C"
  },
  {
    "id": 259,
    "question": "机体在分解代谢过程中产生的最多的酸性物质是",
    "options": ["A.碳酸", "B.乳酸", "C.丙酮酸", "D.磷酸", "E.硫酸"],
    "answer": "A"
  },
  {
    "id": 260,
    "question": "血浆 [HCO3-] 原发性增高可见于",
    "options": ["A.代谢性酸中毒", "B.代谢性碱中毒", "C.呼吸性酸中毒", "D.呼吸性碱中毒", "E.呼吸性酸中毒合并代谢性酸中毒"],
    "answer": "B"
  },
  {
    "id": 261,
    "question": "血浆 [HCO3-] 原发性降低可见于",
    "options": ["A.代谢性酸中毒", "B.代谢性碱中毒", "C.呼吸性酸中毒", "D.呼吸性碱中毒", "E.呼吸性酸中毒合并代谢性碱中毒"],
    "answer": "A"
  },
  {
    "id": 262,
    "question": "血浆 [H2CO3] 原发性升高可见于",
    "options": ["A.代谢性酸中毒", "B.代谢性碱中毒", "C.呼吸性酸中毒", "D.呼吸性碱中毒", "E.呼吸性碱中毒合并代谢性酸中毒"],
    "answer": "C"
  },
  {
    "id": 263,
    "question": "血浆 [H2CO3] 原发性降低可见于",
    "options": ["A.代谢性酸中毒", "B.代谢性碱中毒", "C.呼吸性酸中毒", "D.呼吸性碱中毒", "E.呼吸性酸中毒合并代谢性酸中毒"],
    "answer": "D"
  },
  {
    "id": 264,
    "question": "代谢性酸中毒时细胞外液[H+]升高,其最常与细胞内进行交换的离子是",
    "options": ["A.Na+", "B.K+", "C.Cl-", "D.HCO3-", "E.Ca2+"],
    "answer": "B"
  },
  {
    "id": 265,
    "question": "血液pH的高低取决于血浆中",
    "options": ["A.NaHCO3浓度", "B.PaCO2", "C.CO2CP", "D.[HCO3-]/[H2CO3]", "E.[HCO3-]"],
    "answer": "D"
  },
  {
    "id": 266,
    "question": "碱中毒时出现手足搐搦的主要原因是",
    "options": ["A.血钠降低", "B.血钾降低", "C.血镁降低", "D.血钙降低", "E.血磷降低"],
    "answer": "D"
  },
  {
    "id": 267,
    "question": "不易引起呼吸性酸中毒的是",
    "options": ["A.呼吸性中枢抑制", "B.气道阻塞", "C.肺泡通气量减少", "D.肺通气过度", "E.吸入气中CO2浓度过高"],
    "answer": "D"
  },
  {
    "id": 268,
    "question": "pH 7.18, PaCO2 50 mmHg, [HCO3-] 18 mmol/L,应考虑",
    "options": ["A.代谢性酸中毒伴呼吸性酸中毒", "B.代谢性碱中毒伴呼吸性酸中毒", "C.代谢性酸中毒伴呼吸性碱中毒", "D.代谢性碱中毒伴呼吸性碱中毒", "E.原发性代谢性碱中毒"],
    "answer": "A"
  },
  {
    "id": 269,
    "question": "糖尿病酮症会引起",
    "options": ["A.代谢性碱中毒", "B.代谢性酸中毒", "C.呼吸性酸中毒", "D.呼吸性碱中毒", "E.代谢性碱中毒伴呼吸性酸中毒"],
    "answer": "B"
  },
  {
    "id": 270,
    "question": "AB是衡量酸碱平衡的",
    "options": ["A.一个仅受代谢因素影响的指标", "B.一个仅受呼吸因素影响的指标", "C.一个反映机体有缓冲作用的负离子多少的指标", "D.一个反映血液中 CO2 含量多少的指标", "E.一个既受代谢因素又受呼吸因素影响的指标"],
    "answer": "E"
  },
  {
    "id": 271,
    "question": "阴离子间隙主要反映",
    "options": ["A.血浆中阴离子总量的变化", "B.血浆中阳离子总量的变化", "C.血液中未测定的阴离子和未测定阳离子之差", "D.血浆中除 Cl-以外的阴离子含量变化", "E.血浆中 Na+以外的阳离子含量变化"],
    "answer": "C"
  },
  {
    "id": 272,
    "question": "从动脉抽取血样,如不与大气隔绝,受影响的指标是",
    "options": ["A.AB", "B.SB", "C.BE", "D.BB", "E.SB/BE"],
    "answer": "A"
  },
  {
    "id": 273,
    "question": "急性代谢性酸中毒时,机体最主要的代偿方式是",
    "options": ["A.组织外液缓冲", "B.呼吸代偿", "C.组织内缓冲", "D.肾脏代偿", "E.骨骼代偿"],
    "answer": "B"
  },
  {
    "id": 274,
    "question": "血气分析测定结果为 PaCO2 降低,同时伴 [HCO3-] 升高,可诊断为",
    "options": ["A.呼吸性酸中毒", "B.代谢性酸中毒", "C.代谢性碱中毒", "D.呼吸性碱中毒", "E.呼吸性碱中毒合并代谢性碱中毒"],
    "answer": "E"
  },
  {
    "id": 275,
    "question": "呼吸性碱中毒时可出现",
    "options": ["A.血浆 [K+] 一定升高", "B.血浆[Cl-]一定升高", "C.细胞内乳酸生成减少", "D.细胞内乳酸生成增多", "E.细胞内乳酸生成不变"],
    "answer": "D"
  },
  {
    "id": 276,
    "question": "血液中缓冲固定酸最强的缓冲系统是",
    "options": ["A.Pr-/HPr", "B.Hb/HHb", "C.HCO3-/H2CO3", "D.磷酸氢二钠-磷酸二氢钠缓冲系统", "E.血浆内有机酸缓冲体系"],
    "answer": "C"
  },
  {
    "id": 277,
    "question": "标准碳酸氢盐小于实际碳酸氢盐,见于",
    "options": ["A.代谢性酸中毒", "B.呼吸性酸中毒", "C.呼吸性碱中毒", "D.正常酸碱平衡状态", "E.高阴离子间隙代谢性酸中毒"],
    "answer": "B"
  },
  {
    "id": 278,
    "question": "急性呼吸性酸中毒的代偿调节主要靠",
    "options": ["A.血液的缓冲作用", "B.肺调节作用", "C.细胞内外离子交换", "D.肾的调节作用", "E.其他缓冲系统"],
    "answer": "C"
  },
  {
    "id": 279,
    "question": "关于单纯性代谢性碱中毒的叙述，错误的是",
    "options": ["A.血浆 [HCO3-] 增加", "B.PaCO2 降低", "C.血钙降低", "D.血钾降低", "E.BE正值增加"],
    "answer": "B"
  },
  {
    "id": 280,
    "question": "关于肿瘤发生的叙述，错误的是",
    "options": ["A.肿瘤的发生是多阶段的长期过程", "B.肿瘤的发生是多因素作用的结果", "C.肿瘤的发生只涉及自身因素", "D.肿瘤的发生涉及癌基因的激活", "E.肿瘤的发生在基因水平上"],
    "answer": "C"
  },
  {
    "id": 281,
    "question": "属于肿瘤特异性标志物的是",
    "options": ["A.CA19-9", "B.ALP", "C.PSA", "D.CA125", "E.P53"],
    "answer": "C"
  },
  {
    "id": 282,
    "question": "最早用于临床的肿瘤标志物是",
    "options": ["A.ALP", "B.BJP", "C.CEA", "D.AFP", "E.PSA"],
    "answer": "B"
  },
  {
    "id": 283,
    "question": "关于影响肿瘤标志物检测结果的叙述，错误的是",
    "options": ["A.试剂价格", "B.标本采集时间", "C.药物", "D.HAMA 效应", "E.钩状效应"],
    "answer": "A"
  },
  {
    "id": 284,
    "question": "关于肿瘤标志物的临床意义的叙述，错误的是",
    "options": ["A.用于高危人群恶性肿瘤的筛查", "B.用于肿瘤治疗方案的选择", "C.用于肿瘤预后的判断", "D.用于肿瘤疗效的判断和治疗监测", "E.评估治疗方案"],
    "answer": "B"
  },
  {
    "id": 285,
    "question": "肿瘤标志物联合应用的基本原则是选用不同性质、互补的、相对敏感的标志物组成标志群,一般选用的是",
    "options": ["A.1-2", "B.3~4", "C.5~6", "D.7-8", "E.9-10"],
    "answer": "B"
  },
  {
    "id": 286,
    "question": "鉴别原发性肝癌和转移性肝癌可用",
    "options": ["A.AFU", "B.AFP", "C.LCA 凝集素AFP异质体结合试验", "D.ConA 凝集素AFP异质体结合试验", "E.ALD-A"],
    "answer": "C"
  },
  {
    "id": 287,
    "question": "CEA作为首选标志物的肿瘤是",
    "options": ["A.大肠癌", "B.肺癌", "C.前列腺癌", "D.肝癌", "E.胃癌"],
    "answer": "A"
  },
  {
    "id": 288,
    "question": "卵巢癌的首选标志物是",
    "options": ["A.AFP", "B.CEA", "C.PSA", "D.CA125", "E.CA15-3"],
    "answer": "D"
  },
  {
    "id": 289,
    "question": "乳腺癌的首选标志物是",
    "options": ["A.AFP", "B.CEA", "C.PSA", "D.CA125", "E.CA15-3"],
    "answer": "E"
  },
  {
    "id": 290,
    "question": "CA19-9常用于诊断的是",
    "options": ["A.直肠癌", "B.肺癌", "C.胰腺癌", "D.卵巢癌", "E.乳腺癌"],
    "answer": "C"
  },
  {
    "id": 291,
    "question": "常用于宫颈癌诊断的肿瘤标志物是",
    "options": ["A.CA125", "B.CA19-9", "C.CA153", "D.CEA", "E.SCCA"],
    "answer": "E"
  },
  {
    "id": 292,
    "question": "可用于睾丸母细胞瘤联合检测的项目是",
    "options": ["A.AFP+睾酮", "B.AFP+hCG", "C.AFP+雌激素", "D.hCG+睾酮", "E.hCG+雌激素"],
    "answer": "B"
  },
  {
    "id": 293,
    "question": "产生激素最多的肿瘤是",
    "options": ["A.直肠癌", "B.肺癌", "C.胰腺癌", "D.卵巢癌", "E.乳腺癌"],
    "answer": "B"
  },
  {
    "id": 294,
    "question": "关于抑癌基因的叙述，正确的是",
    "options": ["A.ras 基因", "B.myc基因", "C.p53 基因", "D.bcr/abl 基因", "E.erbB2基因"],
    "answer": "B"
  },
  {
    "id": 295,
    "question": "关于 Cyfra21-1的叙述，正确的是",
    "options": ["A.在小细胞肺癌强表达", "B.在宫颈癌阴性表达", "C.是CK19的不可溶片段", "D.是膀胱癌的辅助诊断标志物", "E.不参与细胞骨架的构成"],
    "answer": "D"
  },
  {
    "id": 296,
    "question": "不宜用肝素抗凝血浆进行TDM的药物是",
    "options": ["A.地高辛", "B.苯妥英", "C.庆大霉素", "D.氨茶碱", "E.环孢素"],
    "answer": "C"
  },
  {
    "id": 297,
    "question": "可以用唾液作为TDM样品的药物是",
    "options": ["A.地高辛", "B.链霉素", "C.庆大霉素", "D.氨茶碱", "E.环孢素"],
    "answer": "D"
  },
  {
    "id": 298,
    "question": "在TDM样品预处理中,需要选择性的浓集待测组分,所采用的方法是",
    "options": ["A.去蛋白", "B.提取", "C.甲基化", "D.磷酸化", "E.衍生化"],
    "answer": "B"
  },
  {
    "id": 299,
    "question": "可用全血样品进行TDM的是",
    "options": ["A.地高辛", "B.苯妥英", "C.庆大霉素", "D.氨茶碱", "E.环孢素"],
    "answer": "E"
  },
  {
    "id": 300,
    "question": "血药浓度存在“治疗窗”现象的是",
    "options": ["A.强心苷类药物", "B.抗心律失常药物", "C.免疫抑制剂", "D.抗癫痫药", "E.三环类抗抑郁药"],
    "answer": "E"
  },
  {
    "id": 301,
    "question": "最常用于TDM的样品是",
    "options": ["A.尿液", "B.脑脊液", "C.胃液", "D.头发", "E.唾液"],
    "answer": "E"
  },
  {
    "id": 302,
    "question": "可用唾液作为治疗药物监测标本的药物是",
    "options": ["A.碳酸锂", "B.地高辛", "C.环孢素", "D.丙戊酸", "E.庆大霉素"],
    "answer": "A"
  },
  {
    "id": 303,
    "question": "药物的消除是指",
    "options": ["A.药物的吸收和分布", "B.药物的分布和生物转化", "C.药物的吸收和生物转化", "D.药物的生物转化和排泄", "E.药物的代谢"],
    "answer": "D"
  },
  {
    "id": 304,
    "question": "关于临床上需测定药物浓度进行监测的主要药物的叙述，错误的是",
    "options": ["A.地高辛", "B.苯妥英钠", "C.阿米替林", "D.青霉素", "E.链霉素"],
    "answer": "D"
  },
  {
    "id": 305,
    "question": "TDM的最主要用途是",
    "options": ["A.筛选中毒药物", "B.进行药物过量时的临床药理学研究", "C.提高用药的依从性", "D.实现给药方案个体化", "E.判断中毒程度"],
    "answer": "D"
  },
  {
    "id": 306,
    "question": "关于TDM 取样时间的叙述，错误的是",
    "options": ["A.一般在达到稳态血药浓度后取样", "B.恒速静脉滴注时达稳态后,任何时间取样", "C.诊断急性药物中毒,应立即取样", "D.观察药物是否达中毒浓度,在谷浓度时取样", "E.多剂量间隔用药时,根据实际需要取样"],
    "answer": "D"
  },
  {
    "id": 307,
    "question": "关于表观分布容积的叙述，错误的是",
    "options": ["A.表观分布容积是为了用血药浓度计算体内药录而引入的比例常数", "B.表观分布容积表示给药剂量或体内药量与血药浓度的一个比值", "C.表观分布容积是一理论容积,无直接的生理意义", "D.表观分布容积并不代表真实的容积", "E.表观分布容积不仅取决于药物本身的理化性质,还取决于患者的身体素质"],
    "answer": "E"
  },
  {
    "id": 308,
    "question": "关于有关地高辛的叙述，错误的是",
    "options": ["A.治疗各种伴有心力衰竭的心脏病", "B.安全范围极小", "C.片剂的生物利用度为60%-80%", "D.酊剂可达80%~100%", "E.血浆蛋白结合率高,为60%-90%"],
    "answer": "E"
  },
  {
    "id": 309,
    "question": "关于有关奎尼丁的叙述，错误的是",
    "options": ["A.最常用的口服抗心律失常药物", "B.治疗指数低,约1/3的患者发生不良反应", "C.生物利用度为45%-98%,个体差异大", "D.蛋白结合率为30%-40%", "E.主要经肾脏排泄"],
    "answer": "D"
  },
  {
    "id": 310,
    "question": "生物体内最稳定的活性氧是",
    "options": ["A.H2O2", "B.OH", "C.O2", "D.O2-", "E.H2O"],
    "answer": "A"
  },
  {
    "id": 311,
    "question": "FOX法可以检测的是",
    "options": ["A.LOOH", "B.AOPP", "C.OH", "D.MDA", "E.NO"],
    "answer": "A"
  },
  {
    "id": 312,
    "question": "关于蛋白质氧化损伤检测中蛋白质羰基化测定的叙述，错误的是",
    "options": ["A.2,4-二硝基苯肼法", "B.硼氢化钠法", "C.荧光胺法", "D.荧光素肼法", "E.硫代巴比妥比色法"],
    "answer": "E"
  },
  {
    "id": 313,
    "question": "关于氧化应激对机体的生理作用的叙述，错误的是",
    "options": ["A.防御作用", "B.参与合成某些重要的生物活性物质", "C.参与细胞膜中的糖分子羟基化", "D.参与解毒作用", "E.参与许多酶促反应"],
    "answer": "C"
  },
  {
    "id": 314,
    "question": "唯一的 OH直接检测方法是",
    "options": ["A.荧光探针法", "B.荧光光度法", "C.激光诱导荧光成像法", "D.自动电位滴定法", "E.HPLC法"],
    "answer": "C"
  },
  {
    "id": 315,
    "question": "过氧化物酶-氧化酶法检测 H2O2 时,体系中的底物是",
    "options": ["A.葡萄糖", "B.NADH", "C.NAD", "D.双氢罗丹明", "E.亚硝酸"],
    "answer": "B"
  },
  {
    "id": 316,
    "question": "体内唯一以 O2- 为底物的酶是",
    "options": ["A.过氧化氢酶", "B.超氧化物歧化酶", "C.谷胱甘肽过氧化物酶", "D.醛酮还原酶", "E.葡萄糖氧化酶"],
    "answer": "B"
  },
  {
    "id": 317,
    "question": "只能清除 LOOH,不能清除H2O2的抗氧化酶是",
    "options": ["A.CAT", "B.GST", "C.SOD", "D.SeGSHPx", "E.NOS"],
    "answer": "B"
  },
  {
    "id": 318,
    "question": "关于帕金森病的产生是由于递质系统受损所致，正确的是",
    "options": ["A.黑质-纹状体多巴胺能系统", "B.脑干网状结构胆碱能系统", "C.纹状体-黑质-氨基丁酸能系统", "D.中缝核5-羟色胺能系统", "E.蓝斑上部去甲肾上腺素能系统"],
    "answer": "A"
  },
  {
    "id": 319,
    "question": "5-HT及5-HIAA上升的是",
    "options": ["A.精神发育迟滞患儿的血液中", "B.抑郁性精神病患者的CSF中", "C.精神分裂症患者的血液中", "D.颅脑外伤疾病患者的CSF中", "E.癫痫患者的CSF中"],
    "answer": "B"
  },
  {
    "id": 320,
    "question": "在正常条件下,脑组织主要利用的能源物质是",
    "options": ["A.葡萄糖", "B.氨基酸", "C.甘油", "D.蛋白质", "E.酮体"],
    "answer": "A"
  },
  {
    "id": 321,
    "question": "关于神经递质的叙述，正确的是",
    "options": ["A.乙酰胆碱", "B.肾上腺素", "C.高香草酸", "D.去甲肾上腺素", "E.多巴胺"],
    "answer": "C"
  },
  {
    "id": 322,
    "question": "关于帕金森病的叙述，错误的是",
    "options": ["A.不属于遗传病", "B.临床表现包括静息时震颤、肌强直、随意运动减慢、姿势不稳定等", "C.光镜下见黑质等区域存在特定类型的神经元变性,并伴有Lewy 小体", "D.CSF中GABA下降", "E.病理主要由于黑质等部位的多巴胺能神经元受损"],
    "answer": "A"
  },
  {
    "id": 323,
    "question": "判断成人CSF中蛋白质总量为病理性增高的标准是",
    "options": ["A.50 mg/L", "B.100 mg/L", "C.150 mg/L", "D.250 mg/L", "E.450 mg/L"],
    "answer": "E"
  },
  {
    "id": 324,
    "question": "CSF蛋白电泳呈现前白蛋白含量下降时,见于",
    "options": ["A.脑积水", "B.脑内炎性疾病", "C.脑外伤", "D.脑萎缩", "E.中枢神经系统退行性变"],
    "answer": "B"
  },
  {
    "id": 325,
    "question": "关于亨廷顿病的叙述，错误的是",
    "options": ["A.CSF中-氨基丁酸含量下降", "B.CSF中ACh含量下降", "C.CSF 中多巴胺水平可能增高", "D.血常规检查一般无异常", "E.尿常规检查异常"],
    "answer": "E"
  }
]